With rise in emerging modalities such as mRNA, antibody-drug conjugates, and gene therapy, we are continually expanding our global capabilities to support our collaborations. Listen to Suresh Swaminathan, Commercial Head for Lipids and Nucleic Acid Delivery, and learn more about our biopharma lab in North America. Want to visit? Sign up for our emails to be the first to know about upcoming events and meet our team! https://lnkd.in/eKbnCfdn
Croda Pharma ’s Post
More Relevant Posts
-
Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy
-
Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy
ON-DEMAND WEBINAR: Key challenges and lab solutions in your global cell and gene therapy trials, Mar. 20, 2024 | Labcorp
share.postbeyond.com
-
Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy
ON-DEMAND WEBINAR: Key challenges and lab solutions in your global cell and gene therapy trials, Mar. 20, 2024 | Labcorp
share.postbeyond.com
-
Chimeric antigen receptor (CAR) T Cell products are human gene therapy products, in which the genetic modification of T Cell specificity allows the recognition of a specific target antigen for therapeutic applications. This FDA final guidance revision adds updated recommendations for the consideration of clinical study design, and PK/PD/TK, as well as chemistry, manufacturing, and control (CMC). Read the guidance below. #DrugDevelopment #GeneTherapy #DrugDiscovery
-
Success in gene therapy requires more than just expertise; it demands a partner who can seamlessly integrate with your vision and objectives. With Andelyn Biosciences, you gain a partner with a proven track record of over 450 clinical batches and 75 global clinical trials. Discover how our experience can ensure your project’s success at any stage, from pre-clinical to commercial. Read our article about optimizing yields and enabling tech transfers. https://buff.ly/3VB3oEP
-
-
Vice President and Enterprise Head of Cell and Gene Therapy at Labcorp Drug Development
Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy
ON-DEMAND WEBINAR: Key challenges and lab solutions in your global cell and gene therapy trials, Mar. 20, 2024 | Labcorp
share.postbeyond.com
-
Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy
ON-DEMAND WEBINAR: Key challenges and lab solutions in your global cell and gene therapy trials, Mar. 20, 2024 | Labcorp
share.postbeyond.com
-
Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy
ON-DEMAND WEBINAR: Key challenges and lab solutions in your global cell and gene therapy trials, Mar. 20, 2024 | Labcorp
share.postbeyond.com
-
Business Development Manager | Progressing your drug development journey - Toxicology, Pharmacology, DMPK, IND Enabling Packages, Supporting Western US
Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy
ON-DEMAND WEBINAR: Key challenges and lab solutions in your global cell and gene therapy trials, Mar. 20, 2024 | Labcorp
share.postbeyond.com
